Conjugated linoleic acid content of human plasma

Spiros N Zlatanos*, Kostas Laskaridis and Angelos Sagredos

Address: Laboratory of Organic Chemistry, Chemical Engineering Dept., Aristotle University of Thessaloniki, GR-541 24, Thessaloniki, Greece
Email: Spiros N Zlatanos* - szlatano@eng.auth.gr; Kostas Laskaridis - kostas_laskaridis@yahoo.gr; Angelos Sagredos - Sagredos@t-online.de
* Corresponding author

Abstract
Conjugated linoleic acid (CLA), a naturally occurring anticarcinogen found in dairy products, is an intermediary product of ruminal biohydrogenation of polyunsaturated fatty acids. Few data exist on the CLA content of the human blood plasma. The determination of a "normal" content could help in estimating if a person consumes satisfactory amounts of CLA with the diet and thus takes advantage of its potential beneficial effects on health. The purpose of this study was to compare the plasma CLA content of individuals not consuming dairy products (group 1, n = 12), individuals consuming normal amounts of dairy products (group 2, n = 77) and individuals consuming CLA supplement (group 3, n = 12). The only CLA isomer that presented higher percentage than the detection limit (0.03% of total fatty acids) was rumenic acid (cis-9, trans-11-octadecadienoic acid). An interesting finding is that compared to the other two groups, group 3 members show the highest average plasma content in rumenic acid, i.e. 0.20% of total fatty acids. The present study could be characterized as the first step in the direction of establishing a normal CLA content of human plasma. Based on these results, it could be suggested that the lower limit of the plasma CLA content is approximately 0.1% of total fatty acids.

Background
Conjugated linoleic acid (CLA) is a term that refers to a group of linoleic acid isomers with conjugated double bonds. In the past two decades there has been an increasing interest in the biological effects of CLA, since Grimm and Pariza [1] reported that dienes in fried ground beef protect against chemically induced cancer. The double bonds of the various CLA isomers could be in positions 7, 9; 8, 10; 9, 11; 10,12; or 11, 13 with cis or trans configuration, but the most abundant isomer in nature is cis-9, trans-11 [2,3]. This isomer is called rumenic acid and is formed by the anaerobic bacteria Butyribrio fibrisolvens in the rumen [4,5].

The richest food sources of CLA are first the dairy products, especially cheese and then ruminant meat [6,7]. CLA isomers can also be produced by heating linoleic acid in the presence of alkaline solutions. The isomerisation of linoleic acid to conjugated dienes was initially reported by von Mikusch [8].

Several animal experiments relate the consumption of CLA to the inhibition of tumorigenesis [9-11] and atherogenesis [12-14], the normalizing of glucose tolerance [15], and the reduction of body fat [16-18]. In several nutritional studies the effect of CLA supplementation on human body composition has been studied. However, the results of these studies showed that CLA had less effect on body fat than it was concluded from in vivo studies. A recent meta-analysis [19] has concluded that a dose of 3.2 g CLA/d produced a modest reduction in fat mass in humans.
It is known that rumenic acid is normally found in human plasma as part of triglycerides, phospholipids and cholesterol esters [20]. However, few data exist concerning the normal concentrations of CLA in human plasma. This kind of information could help to estimate if a person takes satisfactory amounts of CLA with the diet or if there is a need to increase them by supplementation, given its potential effects on health-related parameters.

Mougios et al [21] showed that diet supplementation with small doses of CLA in encapsulated form for 4–8 weeks, may increase the CLA content in human serum. There is no indication if this increase is within the normal levels of a person consuming dairy. Therefore, in the present study, an effort was made to set a “limit” between low and high plasma CLA content. In this direction the plasma fatty acid composition was determined in 101 volunteers divided into three groups: a group not consuming any dairy products, a group consuming normal amounts of dairy products and a group consuming CLA supplements for several months.

**Materials and methods**

**Participants**

Group 1 is comprised of 6 women and 6 men.

Group 2 is comprised of 37 women and 40 men.

Group 3 is comprised of 6 women and 6 men.

Blood samples used in the current study were collected from German volunteers. The age of the volunteers ranged from 18 to 65 years. Individuals were not affected by gastrointestinal or liver diseases, which could influence fatty acid metabolism. All participants were interviewed about their dietary habits and especially about the consumption of milk, cheese and other dairy products. Another 12 volunteers were invited to participate in the study, as they were daily consuming 4 × 500 mg soft gelatin capsules of CLA (CLA 70-Trofocell™, Trofocell™ Ltd, Hamburg, Germany) for a period of 6 months. This Trofocell supplement contains about 35% of cis9, trans11-octadecadienoic acid (rumenic acid) and an equal amount of trans-10, cis-12-octadecadienoic acid.

**Sample preparation**

8–10 mL of venous blood samples were collected in heparin tubes. After centrifugation at 4000 rpm the supernatant blood plasma was separated with a pipette. The blood samples were collected in the morning in the fasted state after a 12 h restriction for meal and drinks.

**Preparation and analysis of fatty acid methyl esters**

To 1 g of plasma, 5 mL n-KOH solution in 90% watery methanol and 0,20 mg heptadecanoic acid methyl ester internal standard in 1 mL hexane were added and the solution was saponified at 4°C overnight. 15 mL of 10% BF3 solution in methanol (BF3 methanolate, Merck) were added and the solution was heated at 60°C for 15 min. Then, it was extracted with 25 mL of hexane. The hexane phase was evaporated in a rotary evaporator until dryness. The residue was dissolved in 0.3 mL of hexane and analyzed with gas chromatography, according to Sagredos & von Leitner [22].

In brief:

**Gas chromatography – Conditions**

*Apparatus*: HEWLETT-PACKARD Auto system; *Column*: Sil 88, 50 m, 0.25 ID, 0,25 μm Film thickness; *Detector*: FID (300°C); *Injection*: 3 μL split 1 to 50 (250°C); *Initial pressure*: 22 psi He; *Temperature program*: 60°C for 5 min isotherm, 5°C/min to 180°C, 16 min isotherm, 5°C/min to 220°C, 15 min isotherm.

The fatty acid methyl esters were identified by comparing their retention times to those of standards. The CLA methyl esters standards were obtained from Cayman (Ann Arbor, MI), while the other standards were obtained from Sigma-Aldrich. The weight of CLA and that of the other fatty acids were obtained from the chromatographs and were transformed to weight percentages (%) of total fatty acids in comparison to internal standard and by utilizing response factors. The quantification limit was 0.03% of total fatty acids. Conventional statistics routines (i.e. Excel spreadsheets) were employed for the statistical analysis.

**Results and discussion**

The plasma fatty acid composition of the three participating groups examined.

**Group 1**

It comprises 12 individuals, who did not consume any dairy products.

**Group 2**

In this group 77 volunteers were participated, who consumed normal amounts of dairy products. It means a consumption of about 300–400 g cheese/week. Cheese is the CLA richest dairy product and the main nutriment for a CLA intake. The weekly intake of milk or other dairy products has not been considered because of their relative low concentrations of CLA [23].

**Group 3**

It comprises 12 participants, who daily, after lunch or dinner, were supplied with 4 × 500 mg CLA Capsules of a total amount of 1.4 g CLA (= 0.7 g rumenic acid and 0.7 g t10, c12-CLA).
The analytical results are summarized in Tables 1, 2 and 3 respectively. In all samples analyzed only the \textit{cis}-9, \textit{trans}-11 isomer of CLA was found in amounts higher than the detection limit. The rumenic acid content of group 1 ranged from 0.05 to 0.09% and averaged 0.08% of total fatty acids. The rumenic acid content of group 2 ranged from 0.05 to 0.33% and averaged 0.14% of total fatty acids, significantly higher than the rumenic acid content of group 1 samples. Finally, the rumenic acid content of group 3 ranged from 0.16 to 0.25% with an average of 0.20% of total fatty acids, significantly higher than the rumenic acid content of the two others groups. The distribution of the rumenic acid values among the three groups of individuals is presented in Figure 1. An interesting finding is that only 15 of the 77 samples of the second group present rumenic acid content comparable to the first group. Group 1 exhibits an average plasma content in rumenic acid of 0.08% of total fatty acids, significantly lower than of group 2, i.e. 0.14% of total fatty acids. It is noteworthy, that group 3 exhibits the highest average plasma content in rumenic acid, i.e. 0.20% of total fatty acids.

These results suggest that the main source of CLA in the diet is milk and dairy products. Also, this finding is in agreement with studies, which revealed that dairy products, especially cheeses due to their high fat content, are rich CLA sources [6,7,23]. On the other hand, 32 of the 77 samples of the second group presented amounts equal to or higher than the lower limit of the third group (supplementation group). The others show lower levels than the lower CLA level of the supplementation group. These data indicate that the supplementation can increase the CLA content of the human blood plasma and is therefore an alternative source of CLA for people who suffer from dairy allergies or do not consume dairy products for other reasons. These results comply with previous ones presented by Mougios et al [21].

Table 1: Blood plasma fatty acid composition (% of total fatty acids) of individuals not consuming dairy products (n = 12) (group 1)

| Fatty acid | Occurrence of value (>0.03%) | Median | Average | Standard Deviation | Minimum | Maximum |
|------------|------------------------------|--------|---------|-------------------|---------|---------|
| C 12:0     | 12                           | 0.12   | 0.13    | 0.09              | 0.05    | 0.38    |
| C 14:0     | 12                           | 1.05   | 1.11    | 0.56              | 0.49    | 2.60    |
| C 14:1ω5   | 12                           | 0.08   | 0.09    | 0.05              | 0.03    | 0.21    |
| C 15:0     | 12                           | 0.22   | 0.26    | 0.09              | 0.17    | 0.50    |
| C 16:0     | 12                           | 23.3   | 23.39   | 2.70              | 18.5    | 27.70   |
| C 16:1ω7τ  | 12                           | 0.20   | 0.21    | 0.07              | 0.08    | 0.40    |
| C 16:1ω9c  | 12                           | 0.31   | 0.32    | 0.09              | 0.21    | 0.48    |
| C 16:1ω7c  | 12                           | 2.10   | 1.94    | 0.79              | 0.87    | 3.30    |
| C 17:0ω7   | 7                            | 0.14   | 0.13    | 0.04              | 0.07    | 0.17    |
| C 18:0     | 12                           | 8.40   | 8.13    | 1.18              | 5.80    | 10.2    |
| C 18:1ω9τ  | 12                           | 0.32   | 0.30    | 0.06              | 0.16    | 0.37    |
| C 18:1ω7t  | 9                            | 0.31   | 0.32    | 0.12              | 0.13    | 0.58    |
| C 18:1ω9c  | 12                           | 16.85  | 18.23   | 3.00              | 15.00   | 24.50   |
| C 18:1ω7c  | 12                           | 1.40   | 1.50    | 0.32              | 1.10    | 2.20    |
| C 18:2ωc   | 12                           | 0.13   | 0.14    | 0.04              | 0.08    | 0.23    |
| C 18:2ωtc  | 10                           | 0.08   | 0.08    | 0.04              | 0.03    | 0.17    |
| C 18:2ωct  | 12                           | 0.17   | 0.19    | 0.04              | 0.14    | 0.28    |
| C 18:2ωctc | 12                           | 0.14   | 0.14    | 0.04              | 0.09    | 0.23    |
| C 18:2ωcc  | 12                           | 25.75  | 25.23   | 4.96              | 16.9    | 32.1    |
| C 20:0     | 9                            | 0.06   | 0.07    | 0.02              | 0.04    | 0.12    |
| C 18:3ω6   | 12                           | 0.39   | 0.34    | 0.12              | 0.12    | 0.50    |
| C 20:1ω9   | 12                           | 0.13   | 0.17    | 0.09              | 0.09    | 0.42    |
| C 18:3ω3   | 12                           | 0.51   | 0.54    | 0.21              | 0.33    | 1.00    |
| c9, t11-CLA | 12                          | 0.08   | 0.08    | 0.01              | 0.05    | 0.09    |
| t10, c12-CLA | <0.03                      | <0.03  | <0.03   | <0.03             | <0.03   | <0.03   |
| C 18:4ω3   | 3                            | 0.24   | 0.24    | 0.02              | 0.21    | 0.26    |
| C 20:2ω6   | 12                           | 0.23   | 0.22    | 0.02              | 0.17    | 0.25    |
| C 22:0     | 11                           | 0.15   | 0.16    | 0.05              | 0.08    | 0.25    |
| C 20:3ω6   | 12                           | 1.35   | 1.39    | 0.23              | 0.96    | 1.80    |
| C 20:4ω6   | 12                           | 7.20   | 6.83    | 1.57              | 4.00    | 9.20    |
| C 20:5ω3 (EPA) | 12                         | 0.81   | 0.88    | 0.35              | 0.17    | 1.50    |
| C 22:4ω6   | 12                           | 0.22   | 0.22    | 0.05              | 0.11    | 0.33    |
| C 22:5ω3 (DPA) | 12                      | 0.65   | 0.67    | 0.15              | 0.42    | 1.00    |
| C 22:6ω3 (DHA) | 12                      | 2.40   | 2.55    | 0.85              | 1.20    | 4.30    |
| Total fatty acids (μg/g) | 12                         | 2464   | 2581    | 669              | 1483    | 3948    |
It was additionally of interest to find out, if the CLA supplementation has an influence on the composition of the total amount of saturated and unsaturated fatty acids and on the ratio of ω-6- to ω-3-fatty acids in the blood plasma.

The corresponded comparison data of the three groups were calculated from the tables 1, 2 and 3 and are expressed as % the total fatty acids (Table 4). The CLA supplementation shows obvious a significantly effect on the total saturated fatty acids and the ω-6-fatty acids. CLA reduces the total saturated fatty acids as well as the total ω-6-fatty acids and especially the arachidonic acid. This corresponds to a reduction of the ratio of ω-6-fatty acids and arachidonic acid to ω-3-fatty acids. CLA appears to react as antagonist against ω-6-fatty acids and arachidonic acid. The last is of importance, because a low ratio of ω-6- to ω-3-fatty acids is a valuable determinant of health [22,24].

These effects of CLA on saturated acids and ω-6-fatty acids have to be confirm through further studies with a higher number of test persons.

The present study could be characterized as a first step in the direction of establishing a normal CLA content of human blood plasma. Based on these results, it could be suggested that the lower limit of the blood plasma CLA content is approximately 0.1% of total fatty acids. Thus, individuals who present rumenic acid levels within the range of the first group, namely up to 0.09% of total fatty acids, should consider increasing their CLA uptake through dairy products and/or supplements and could serve as ideal participants in future CLA supplementation studies.

It was additionally of interest to find out, if the CLA supplementation has an influence on the composition of the total amount of saturated and unsaturated fatty acids and on the ratio of ω-6- to ω-3-fatty acids in the blood plasma.

The corresponded comparison data of the three groups were calculated from the tables 1, 2 and 3 and are expressed as % the total fatty acids (Table 4). The CLA supplementation shows obvious a significantly effect on the total saturated fatty acids and the ω-6-fatty acids. CLA reduces the total saturated fatty acids as well as the total ω-6-fatty acids and especially the arachidonic acid. This corresponds to a reduction of the ratio of ω-6-fatty acids and arachidonic acid to ω-3-fatty acids. CLA appears to react as antagonist against ω-6-fatty acids and arachidonic acid. The last is of importance, because a low ratio of ω-6- to ω-3-fatty acids is a valuable determinant of health [22,24].

These effects of CLA on saturated acids and ω-6-fatty acids have to be confirm through further studies with a higher number of test persons.

The present study could be characterized as a first step in the direction of establishing a normal CLA content of human blood plasma. Based on these results, it could be suggested that the lower limit of the blood plasma CLA content is approximately 0.1% of total fatty acids. Thus, individuals who present rumenic acid levels within the range of the first group, namely up to 0.09% of total fatty acids, should consider increasing their CLA uptake through dairy products and/or supplements and could serve as ideal participants in future CLA supplementation studies.

Table 2: Blood plasma fatty acid composition (% of total fatty acids) of individuals consuming normal amounts of dairy products (n = 77) (group 2)

| Fatty acid | Occurrence of value (>0.03%) | Median | Average | Standard Deviation | Minimum | Maximum |
|-----------|------------------------------|-------|---------|--------------------|---------|---------|
| C 12:0    | 76                           | 0.19  | 0.22    | 0.13               | 0.07    | 0.74    |
| C 14:0    | 77                           | 1.40  | 1.50    | 0.64               | 0.49    | 3.30    |
| C 14:1 ω5 | 76                           | 0.10  | 0.12    | 0.07               | 0.03    | 0.35    |
| C 15:0    | 77                           | 0.33  | 0.33    | 0.11               | 0.13    | 0.77    |
| C 16:0    | 77                           | 24.40 | 24.34   | 2.63               | 17.00   | 29.90   |
| C 16:1 ω7 t | 77                  | 0.23  | 0.23    | 0.08               | 0.05    | 0.43    |
| C 16:1 ω9 c | 76                  | 0.36  | 0.36    | 0.11               | 0.07    | 0.88    |
| C 16:1 ω7 c | 77                  | 2.00  | 2.15    | 0.89               | 0.36    | 4.70    |
| C 17:1 ω7 | 77                           | 0.17  | 0.16    | 0.06               | 0.03    | 0.30    |
| C 18:0    | 77                           | 7.60  | 7.78    | 1.11               | 5.20    | 11.9    |
| C 18:1 ω9 t | 70                  | 0.355 | 0.37    | 0.17               | 0.13    | 1.30    |
| C 18:1 ω7 t | 58                  | 0.32  | 0.34    | 0.13               | 0.06    | 0.84    |
| C 18:1 ω9 c | 77                  | 19.3  | 19.44   | 3.10               | 11.6    | 28.2    |
| C 18:1 ω7 c | 77                  | 1.50  | 1.51    | 0.34               | 0.92    | 2.80    |
| C 18:1 ω6 c | 59                  | 0.10  | 0.11    | 0.04               | 0.03    | 0.18    |
| C 18:2 ω6 tt | 72             | 0.08  | 0.09    | 0.05               | 0.03    | 0.23    |
| C 18:2 ω6 ct | 77             | 0.19  | 0.20    | 0.05               | 0.12    | 0.33    |
| C 18:2 ω6 tc | 77             | 0.14  | 0.15    | 0.04               | 0.08    | 0.28    |
| C 18:2 ω6 cc | 77             | 24.20 | 24.81   | 5.01               | 14.20   | 37.40   |
| C 20:0    | 74                           | 0.06  | 0.08    | 0.05               | 0.02    | 0.24    |
| C 18:3 ω6 | 77                           | 0.29  | 0.30    | 0.11               | 0.08    | 0.83    |
| C 20:1 ω9 | 77                           | 0.15  | 0.15    | 0.05               | 0.06    | 0.30    |
| C 18:3 ω3 | 77                           | 0.50  | 0.59    | 0.41               | 0.25    | 3.30    |
| c9, t11-CLA | 77                   | 0.14  | 0.14    | 0.05               | 0.05    | 0.33    |
| t10, c12-CLA | <0.03           | <0.03 | <0.03   | 0.03               | 0.03    | 0.03    |
| C 18:4 ω3 | 15                           | 0.12  | 0.14    | 0.07               | 0.06    | 0.35    |
| C 20:2 ω6 | 77                           | 0.22  | 0.22    | 0.05               | 0.13    | 0.40    |
| C 22:0    | 74                           | 0.15  | 0.16    | 0.06               | 0.04    | 0.34    |
| C 20:3 ω6 | 77                           | 1.40  | 1.39    | 0.34               | 0.57    | 2.30    |
| C 22:1 ω11 | 2                 | 0.035 | 0.04    | 0.01               | 0.03    | 0.04    |
| C 20:4 ω6 | 77                           | 5.30  | 5.41    | 1.43               | 2.50    | 9.10    |
| C 20:5 ω3 | 77                           | 0.64  | 0.75    | 0.44               | 0.19    | 2.50    |
| C 22:4 ω6 | 76                           | 0.19  | 0.19    | 0.06               | 0.04    | 0.41    |
| C 22:5 ω3 | 77                           | 0.52  | 0.56    | 0.16               | 0.34    | 1.10    |
| C 22:6 ω3 | 77                           | 1.80  | 1.91    | 0.77               | 0.70    | 4.30    |
| Total fatty acids (μg/g) | 77 | 2553 | 2834 | 890 | 1438 | 6093 |
Table 3: Blood plasma fatty acid composition (% of total fatty acids) of individuals consuming CLA supplements*) (n = 12) (group 3)

| Fatty acid | Occurrence of value (>0.03%) | Median | Average | Standard Deviation | Minimum | Maximum |
|------------|-------------------------------|--------|---------|--------------------|---------|---------|
| C 12:0     | 7                             | 0.20   | 0.25    | 0.10               | 0.14    | 0.39    |
| C 14:0     | 12                            | 1.80   | 1.72    | 0.73               | 0.55    | 2.70    |
| C 14:1ω5   | 4                             | 0.20   | 0.15    | 0.09               | 0.04    | 0.27    |
| C 15:0     | 12                            | 0.39   | 0.42    | 0.20               | 0.18    | 0.77    |
| C 16:0     | 12                            | 25.40  | 25.53   | 1.72               | 22.50   | 28.80   |
| C 16:1ω7 t | 12                            | 0.20   | 0.22    | 0.12               | 0.05    | 0.38    |
| C 16:1ω7 c | 12                            | 2.60   | 2.57    | 1.13               | 4.70    | 0.66    |
| C 17:1ω7   | 11                            | 0.19   | 0.18    | 0.08               | 0.07    | 0.27    |
| C 18:0     | 12                            | 6.70   | 6.01    | 1.08               | 9.50    | 9.20    |
| C 18:1ω9 t | 12                            | 0.45   | 0.43    | 0.16               | 0.17    | 0.69    |
| C 18:1ω7 t | 6                             | 0.17   | 0.26    | 0.16               | 0.13    | 0.49    |
| C 18:1ω9 c | 12                            | 20.30  | 19.99   | 2.29               | 15.50   | 23.50   |
| C 18:1ω7 c | 12                            | 1.50   | 1.61    | 0.40               | 1.10    | 2.20    |
| C 18:1ω6 c | 8                             | 0.11   | 0.12    | 0.03               | 0.08    | 0.16    |
| C 18:2ω6 cc| 12                            | 0.20   | 0.22    | 0.07               | 0.14    | 0.33    |
| C 18:2ω6 cc| 12                            | 0.16   | 0.17    | 0.06               | 0.09    | 0.28    |
| C 18:2ω6 cc| 12                            | 21.00  | 22.34   | 6.32               | 14.20   | 34.5    |
| C 20:0     | 12                            | 0.04   | 0.06    | 0.03               | 0.03    | 0.13    |
| C 18:3ω6   | 12                            | 0.30   | 0.33    | 0.11               | 0.17    | 0.49    |
| C 20:1ω9   | 12                            | 0.14   | 0.15    | 0.03               | 0.10    | 0.19    |
| C 18:3ω3   | 12                            | 0.53   | 0.89    | 0.99               | 0.36    | 3.30    |
| c9, t11-CLA| 12                            | 0.19   | 0.20    | 0.02               | 0.16    | 0.25    |
| t10, c12-CLA| 12                         | <0.03  | <0.03    |                     |         |         |
| C 18:4ω3   | 4                             | 0.13   | 0.13    | 0.04               | 0.09    | 0.17    |
| C 20:2ω6   | 12                            | 0.19   | 0.19    | 0.02               | 0.17    | 0.24    |
| C 22:0     | 11                            | 0.13   | 0.12    | 0.05               | 0.04    | 0.19    |
| C 20:3ω6   | 12                            | 1.30   | 1.27    | 0.20               | 0.86    | 1.50    |
| C 20:4ω6   | 12                            | 4.30   | 4.11    | 0.95               | 2.50    | 5.30    |
| C 20:5ω3 (EPA)| 12                        | 0.75   | 1.12    | 0.72               | 0.29    | 2.50    |
| C 22:4ω6   | 12                            | 0.19   | 0.17    | 0.08               | 0.04    | 0.28    |
| C 22:5ω3 (DPA)| 12                        | 0.56   | 0.60    | 0.19               | 0.38    | 0.96    |
| C 22:6ω3 (DHA)| 12                        | 1.40   | 1.93    | 1.19               | 0.83    | 4.30    |
| Total fatty acids (μg/g) | 12 | 2571 | 2778 | 573 | 2111 | 3918 |

*) The daily supplementation was 4 × 500 mg CLA Capsules with a total amount of about 700 mg c9, t11-CLA and 700 mg t10, c12-CLA.

Figure 1
Distribution of the CLA values among the three groups of individuals.
### Table 4: Comparison data of the total saturated and unsaturated blood plasma fatty acid composition (% of total fatty acids) of groups 1, 2 and 3

| SATURATED AND UNSATURATED FATTY ACIDS (%) | GROUP 1 AVERAGE % OF TOTAL FATTY ACIDS | GROUP 2 AVERAGE % OF TOTAL FATTY ACIDS | GROUP 3 AVERAGE % OF TOTAL FATTY ACIDS |
|-------------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
| Total saturated fatty acids                | 38.57                                  | 36.47                                  | 34.11                                  |
| Total monounsaturated fatty acids          | 27.08                                  | 26.44                                  | 26.10                                  |
| Total polyunsaturated fatty acids, of them | 34.34                                  | 37.08                                  | 33.71                                  |
| of them ω-6-fatty acids*                   | 32.06                                  | 30.22                                  | 26.45                                  |
| of them arachidonic acid                   | 6.83                                   | 5.41                                   | 4.11                                   |
| ω-3-fatty acids*                           | 4.10                                   | 3.22                                   | 3.65                                   |
| Ratio of ω-6 to ω-3-fatty acids*           | 7.80                                   | 9.38                                   | 7.24                                   |
| Ratio of Arachidonic acid to EPA+DPA+DHA  | 1.66                                   | 1.68                                   | 1.12                                   |

*) The essential ω-6-fatty acids linoleic acid and arachidonic acid and the essential eicosanoids ω-3-fatty acids EPA, DPA and DHA have been only considered.

### Competing interests
The authors declare that they have no competing interests.

### Authors’ contributions
SNZ conceived, designed and coordinated the study. KL carried out the experiments. AS performed the statistical analysis. All authors read and approved the final manuscript.

### References
1. HA YL, Grimm NK, Pariza MW: Anticarcinogens from fried ground beef: Heat-altered derivatives of linoleic acid. Carcinogenesis 1987, 8:1881-1887.
2. MacDonald HB: Conjugated linoleic acid and disease prevention: a review of current knowledge. J Am Coll Nutr 2000, 19:1115-1185.
3. Rainer L, Heiss CJ: Conjugated Linoleic Acid: Health Implications and Effects on Body Composition. J Am Diet Assoc 2004, 104:963-968.
4. Kepler CR, Hirons KP, McNeill JJ, Tove SB: Intermixes and products of the biohydrogenation of linoleic acid by Butyribrio fibrisolvens. J Biol Chem 1966, 241:1350-1354.
5. Kepler CR, Tove SB: Linoleate cis-12, trans-11 isomerase. In Methods in Enzymology Volume XIX. Edited by: Lowenstein JM. Academic Press, New York; 1969:105-110.
6. Chin SF, Liu W, Storkson JM, HA YL, Pariza MW: Dietary sources of conjugated dienoic isomers of linoleic acid, a newly recognized class of anticarcinogens. J Food Comp Anal 1992, 5:185-197.
7. Lin H, Boyston TD, Chang MJ, Lueddeke LO, Shultz TD: Survey of the conjugated linoleic acid content of dairy products. J Dairy Sci 1995, 78:2358-2365.
8. Von Mikusch JD: The alkali isomerization of dehydrated castor oil with a proposed test based on the formation of solid 10, 12-octadecadienoic acid. Lack Farben Chem 1949, 9:101-110.
9. IP C, Chin SF, Scimeca JA, Pariza M: Mammary cancer prevention by conjugated dienoic derivative of linoleic acid. Cancer Res 1991, 51:6118-6124.
10. Belury MA: Conjugated dienoic linoleate: a polysaturated fatty acid with unique chemoprotective properties. Nutr Rev 1993, 51:83-89.
11. IP C: Review of the effects of trans fatty acids, oleic acid, n-3 polysaturated fatty acids, and conjugated linoleic acid on mammary carcinogenesis in animals. Am J Clin Nutr 1997, 66:1523S-1529S.
12. Lee KN, Kritchevsky D, Pariza M: Conjugated linoleic acid and atherosclerosis in rabbits. Atherosclerosis 1994, 108:19-25.
13. Nicolosi RJ, Rogers EJ, Kritchevsky D, Scimeca JA, Huth PJ: Dietary conjugated linoleic acid reduces plasma lipoproteins and early aortic atherosclerosis in hypercholesterolemic hamsters. Artery 1997, 22:266-277.
14. Kritchevsky D, Tepper SA, Wright S, TSO P, Czarnecki SK: Influence of conjugated linoleic acid (CLA) on establishment and progression of atherosclerosis in rabbits. J Am Coll Nutr 2000, 19:472S-477S.
15. Houseknecht KL, Heuvel JP Van Den, Moya-Camarena SY, Portocarrero CP, Peck LW, Nickel KP, Belury MA: Dietary conjugated linoleic acid normalizes impaired glucose tolerance in the Zucker diabetic fatty fa/fa rat. Biochem Biophys Res Commun 1998, 144:678-682.
16. Park Y, Albright KJ, Liu W, Storkson LM, Cook ME, Pariza MW: Effect of conjugated linoleic acid on body composition in mice. Lipids 1997, 32:853-858.
17. West DB, Delany JP, Camet PM, Blohm F, Truett AA, Scimeca J: Effects of conjugated linoleic acid on body fat energy metabolism in the mouse. Am J Physiol 1998, 276:667-672.
18. De Lany JP, Blohm F, Truett AA, Scimeca JA, West DB: Conjugated linoleic acid rapidly reduces body fat content in mice without affecting energy intake. Am J Physiol 1999, 276:1172-1179.
19. Whigham LD, Watras AC, Schoeller DA: Efficacy of conjugated linoleic acid for reducing fat mass: A meta-analysis in humans. American Journal of Clinical Nutrition 2007, 85(5):1203-1211.
20. Inversen SA, CaWood P, Madigan MJ, Lawson AM, Dormandy TL: Identification of a diene conjugated component of human lipid as octadeca-9,11-dienoic acid. FEBS Lett 1984, 171:320-324.
21. Mougiou V, Matasaka A, Petriroud A, Ring S, Sagredos A, Melissopoulou A, Tsigilis N, Nikolaidis M: Effect of supplementation with conjugated linoleic acid on human serum lipids and body fat. J Nutr Biochem 2001, 12:585-594.
22. Sagredos AN, Von Leitner HJ: Zusammenhänge zwischen der Erythrozyten- und Serum-Fettsäuren-zusammensetzung und dem Gehalt an Selen und Vitamin E von Hypertonikern und Normotomikern. Fette Seifen Anstrichm 1986, 88:569-574.
23. Zlatanos S, Laskaridis K, Feist C, Sagredos A: CLA content and fatty acid composition of Greek feta and hard cheeses. Eur J Lipid Sci Technol 2002, 78:471-477.
24. Riemersma RA: The demise of n-6 to n-3 fatty acid ratio? A dossier. Eur J Lipid Sci Technol 2001, 103:372-373.